P1163: OUTCOMES OF HIGH-RISK LARGE B-CELL LYMPHOMA TREATED WITH STANDARD OF CARE CHEMOIMMUNOTHERAPY: A NON-RANDOMIZED COMPARISON TO FRONTLINE CAR-T CELL THERAPY
Main Authors: | O. Albanyan, O. Castaneda-Puglianini, J. Chavez |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000847520.82769.e5 |
Similar Items
-
The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
by: Omar Albanyan, et al.
Published: (2022-12-01) -
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma
by: Reid W. Merryman, et al.
Published: (2023-02-01) -
Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy
by: Hiu Lam Agnes Yuen, et al.
Published: (2020-08-01) -
Immunogenicity of COVID ‐19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy
by: Lim, YJ, et al.
Published: (2024) -
P1163: ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
by: Xiyuan Zhang, et al.
Published: (2023-08-01)